

DAFTAR PUSTAKA

- Almatsier, S., 2004. *Prinsip Dasar Ilmu Gizi*. PT. Gramedia Pustaka Utama, Jakarta.
- Al-Qazaz, H.K., Hassali, M.A., Shafie, A.A., Sulaiman, S.A., Sundram, S., dan Morisky, D.E., 2010. The eight-item Morisky Medication Adherence Scale MMAS: Translation and validation of the Malaysian version. *Diabetes Research and Clinical Practice*, **90**: 216–221.
- Anez, C.R., Reis, R.S., dan Petroski, E.L., 2008. Brazilian Version of a Lifestyle Questionnaire: Translation and Validation for Young Adults. *Arq Bras Cardiol*, **91(2)**:92-98 .
- Anwar, T.B., 2004. *Dislipidemia Sebagai Faktor Risiko Penyakit Jantung Koroner*. FK. USU, Medan.
- Arsana, P., Rosandi, R., Manaf, A., dan Budhiarta, A., 2015. Panduan Pengelolaan Dislipidemia PERKENI.
- Babu, S., M, S., dan Mounika, K., 2014. Study of Prevalence of Dyslipidemia in Women with Diabetes Mellitus - A Cross Sectional Study. *International Journal of Health Sciences & Research*, **4**: 95–98.
- Bangun, A., 2005. *Terapi Jus Dan Ramuan Tradisional Untuk Kolesterol*. Agro Media Pustaka, Jakarta.
- Barkas, F., Liberopoulos, E., dan Elisaf, M., 2013. Impact of compliance with antihypertensive and lipid-lowering treatment on cardiovascular risk benefits. *Hellenic J Atheroscler*, **1**: 18–25.
- Barreto, M. da S., Reiners, A.A.O., dan Marcon, S.S., 2014. Knowledge about hypertension and factors associated with the non-adherence to drug therapy. *Revista Latino-Americana de Enfermagem*, **22**: 491–498.
- Berglund, E., Lytsy, P., dan Westerling, R., 2013. Adherence to and beliefs in lipid-lowering medical treatments: A structural equation modeling approach including the necessity-concern framework. *Patient Education and Counseling*, **91**: 105–112.
- Bolli, P., 2014. Treatment of dyslipidemia: The problem of reaching the goal. *Elsevier*, **236**: 142-143.

- Catapano, A., Casula, M., dan Tragni, E., 2012. Adherence to lipid-lowering treatment: the patient perspective. *Patient Preference and Adherence*, **6**: 805-811.
- Crichton, G.E. dan Alkerwi, A., 2015. Physical activity, sedentary behavior time and lipid levels in the Observation of Cardiovascular Risk Factors in Luxembourg study. *Lipids in Health and Disease*, **14**:87.
- de Oliveira-Filho, A.D., Morisky, D.E., Neves, S.J.F., Costa, F.A., dan de Lyra, D.P., 2014. The 8-item Morisky Medication Adherence Scale: Validation of a Brazilian–Portuguese version in hypertensive adults. *Research in Social and Administrative Pharmacy*, **10**: 554–561.
- Dipiro, J.T., 2005. *Pharmacotherapy: A Pathophysiologic Approach*. McGraw-Hill Medical, New York.
- Eghan, B.A. dan Acheampong, J.W., 2003. Dyslipidemia in outpatients at General Hospital in Kumasi, Ghana: cross-sectional study. *Croatian medical journal*, **44**: 576–578.
- Erwinanto, Santoso, A., dan Putranto, J.N., 2013. Pedomannya_tataaksana_Dislipidemia (PERKI).pdf.
- Feingold, K.R. dan Grunfeld, C., 2015. Obesity and Dyslipidemia, dalam: De Groot, L.J., Chrousos, G., Dungan, K., Feingold, K.R., Grossman, A., Hershman, J.M., dkk. (Editor), *Endotext*. MDText.com, Inc., South Dartmouth (MA).
- Gau, G.T. dan Wright, R.S., 2006. Pathophysiology, Diagnosis, and Management of Dyslipidemia. *Current Problems in Cardiology*, **31**: 445–486.
- Grover, A., Rehan, H.S., Gupta, L.K., dan Yadav, M., 2017. Correlation of compliance to statin therapy with lipid profile and serum HMGCoA reductase levels in dyslipidemic patients. *Indian Heart Journal*, **69**: 6–10.
- Grundy, M., Becker, D., dan Clark, L., 2002. 'National Cholesterol Education Program', , *PhD Thesis*, . National Heart, Lung, and Blood Institute.
- Halperin, R.O., Sesso, H.D., Ma, J., Buring, J.E., Stampfer, M.J., dan Michael Gaziano, J., 2006. Dyslipidemia and the Risk of Incident Hypertension in Men. *Hypertension*, **47**: 45–50.

- He Huan, Yu, Y.Q., dan Kuo, C.G., 2014. Dyslipidemia awareness, treatment, control and influence factors among adults in the Jilin province in China: a cross-sectional study. *Lipid in Health and Disease*, **13**: 1–9.
- Hungu, 2007. *Demografi Kesehatan Indonesia* . Grasindo, Jakarta.
- Jellinger, P.S., Handelsman, Y., Rosenblit, P.D., Bloomgarden, Z.T., Fonseca, V.A., Garber, A.J., dkk., 2017a. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. *Endocrine Practice*, **23**: 1–87.
- John, L., Esheiba, E., Fathi, M., Agarwal, A., Sreedharan, J., Muttappallymyalil, J., dkk., 2014. Efficacy of Statins in Dyslipidemia: A Non interventional comparative study in a tertiary care hospital, Ajman, UAE. *Nepal Journal of Epidemiology*, **4(5)**:428-432.
- Junge, C. dan Freeman, M.W., 2005. Lowering your cholesterol. Cambridge. *Tata McGraw-Hill*, .
- Kleppe, M., 2016. Understanding Medication Adherence: A Self-report Measure and A Dual-Process Framework.
- Kleppe, M., Lacroix, J., Ham, J., dan Midden, C., 2015. The development of the ProMAS: a Probabilistic Medication Adherence Scale. *Patient Preference and Adherence*, **9**: 355-367.
- Klop, B., Elte, J., dan Cabezas, M., 2013. Dyslipidemia in Obesity: Mechanisms and Potential Targets. *Nutrients*, **5**: 1218–1240.
- Korb-Savoldelli, V., Gillaizeau, F., Pouchot, J., Lenain, E., Postel-Vinay, N., Plouin, P.-F., dkk., 2012. Validation of a French Version of the 8-Item Morisky Medication Adherence Scale in Hypertensive Adults: Validation of a French Version of MMAS. *The Journal of Clinical Hypertension*, **14**: 429–434.
- Kristina, S.A., Endarti, D., Andayani, T.M., dan Rokhman, M.R., 2017. Reliability And Validity Of Hypothetical Scenarios For Estimating Willingness To Pay (Wtp) Per Quality Adjusted Life Year (Qaly) In Indonesia Setting. *International Journal of Pharmacy and Pharmaceutical Sciences*, **9**: 288-289.
- Lalonde, L., Gray-Donald, K., Lowensteyn, I., Marchand, S., Dorais, M., Michaels, G., dkk., 2002. Comparing the Benefits of Diet and Exercise in the Treatment of Dyslipidemia. *Preventive Medicine*, **35**: 16–24.

Lee, S., Bae, Y., Worley, M., dan Law, A., 2017. Validating the Modified Drug Adherence Work-Up (M-DRAW) Tool to Identify and Address Barriers to Medication Adherence. *Pharmacy*, **5**: 52.

Malhotra, N., Keshan, M., dan Agarwal, A., 2016. Demographic Assessment and Evaluation of Degree of Lipid Control in High Risk Indian Dyslipidemia Patients (DIVERSE Study). *Journal of The Association of Physicians of India*, **64**: 38–46.

Mann J dan Skeaff M, 2002. *Lipids Di Dalam Mann J and A S Trusswell (Eds) 2002. Essential of human nutrition. 2nd edition., Oxford.*

Marzec, L.N. dan Maddox, T.M., 2013. Medication Adherence in Patients with Diabetes and Dyslipidemia: Associated Factors and Strategies for Improvement. *Current Cardiology Reports*, **15**: 418-425.

Matson, J.L. dan Nebel-Schwalm, M.S., 2007. Comorbid psychopathology with autism spectrum disorder in children: An overview. *Research in Developmental Disabilities*, **28**: 341–352.

Mayes, P., J.R. M., W, D., dan Rodwell, V.W., 2009. *Harper's Review of Biochemistry*.

Meagher, E.A., 2004. Addressing cardiovascular disease in women: focus on dyslipidemia. *The Journal of the American Board of Family Practice*, **17**: 424–437.

Mithal, A., Majhi, D., Shunmugavelu, M., Talwarkar, P.G., Vasawala, H., dan Raza, A.S., 2014. Prevalence of dyslipidemia in adult Indian diabetic patients: A cross sectional study (SOLID). *Indian journal of endocrinology and metabolism*, **18**: 642-645.

Moharamzad, Y., Saadat, H., Nakhjavan Shahraki, B., Rai, A., Saadat, Z., Aerab-Sheibani, H., dkk., 2015. Validation of the Persian Version of the 8-Item Morisky Medication Adherence Scale (MMAS-8) in Iranian Hypertensive Patients. *Global Journal of Health Science*, **7**: 173-181.

Murray, R., Dayl, K., Peter, A., dan Victor, w, 2003. *Biokimia Harper*. EGC, Jakarta.

Nam, G.E., Cho, K.H., Park, Y.G., Han, K.D., Choi, Y.S., Kim, S.M., dkk., 2013. Socioeconomic status and dyslipidemia in Korean adults: The 2008–2010 Korea National Health and Nutrition Examination Survey. *Preventive Medicine*, **57**: 304–309.

- Nursalam, 2008. , dalam: *Konsep Dan Penerapan Metodologi Penelitian Ilmu Keperawatan. Edisi 2*. Salemba Medika, Jakarta.
- Okello, S., Nasasira, B., Muiru, A.N.W., dan Musingo, A., 2016. Validity and reliability of a self-reported measure of antihypertensive medication adherence in Uganda. *PloS one*, **11**: 1-11..
- Oliveira, M.R., Costa, I.F.A.F. da, Farias, C.R.L. de, Simões, M.O. da S., Medeiros, C.C.M., dan Carvalho, D.F. de, 2014. Practice of Physical Activity and Its Relationship with Lipid Profile of Adolescents. *Health*, **06**: 2356–2363.
- Osterberg, L. dan Blaschke, T., 2005. Adherence to medication. *New England Journal of Medicine*, **353**: 487–497.
- Qi, L., Ding, X., Tang, W., Li, Q., Mao, D., dan Wang, Y., 2015. Prevalence and Risk Factors Associated with Dyslipidemia in Chongqing, China. *International Journal of Environmental Research and Public Health*, **12**: 1-11.
- Reiner, Z., Catapano, A.L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., dkk., 2011. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *European Heart Journal*, **32**: 1769–1818.
- Russo, G.T., Giandalia, A., Romeo, E.L., dan Cucinotta, D., 2015. Gender differences in lipoprotein metabolism. *Italian Journal of Gender-Specific Medicine*, **1**: 58–65.
- Sabaté, E. (Editor), 2003. *Adherence to Long-Term Therapies: Evidence for Action*. World Health Organization, Geneva.
- Saleem, F., Hassali, M.A., Shafie, A.A., Awad, A.G., dan Bashir, S., 2011. Association between knowledge and drug adherence in patients with hypertension in Quetta, Pakistan. *Tropical Journal of Pharmaceutical Research*, **10(2)**: 125-132.
- Shanmugasundaram, M., Rough, S.J., dan Alpert, J.S., 2010. Dyslipidemia in the Elderly: Should it Be Treated? *Clinical Cardiology*, **33**: 4–9.
- Soeharto, I., 2004. *Pencegahan Penyakit Jantung Koroner*. PT. Gramedia Pustaka Utama, Jakarta.

- Sofian, A., 2005. *Potensi Produk Fermentasi Kacang Kedelai Sebagai Pengendali Kadar Kolesterol Darah (Skripsi)*. Fakultas Matematika dan Ilmu pengetahuan alam IPB.
- Sonagra, A.D., Shylaja, T.V., Makandar, A., dan Deba, Z., 2017. Study of Lipid Profile among Healthy Smokers and Non Smokers. *International Journal of Biotechnology and Biochemistry*, **13**: 87–94.
- Sorace, P., 2006. Exercise, physical activity, and dyslipidemia. *Strength and Conditioning Journal*, **28**: 57.
- Tan, N.C., Koh, E.Y.L., Goh, C.C., Goh, P.S.C., dan Koh, K.H., 2017. A cross-sectional study of gender differences in lifestyle behavior and usage of medications among community-dwelling Asians towards achieving their LDL-Cholesterol treatment goals. *Proceedings of Singapore Healthcare*, **26**: 158–165.
- Teramoto, T., Sasaki, J., Ishibashi, S., dan Birou, S., 2012. Diagnostic Criteria for Dyslipidemia Executive summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan 2012 Version. *Journal of Atherosclerosis and Thrombosis*, **20**: 655-658.
- Tharaheswari, M. dan Yogamoorthi, A., 2014. Studies on dyslipidemia in diabetic and non diabetic hypertensive patients. *Studies*, **2**: 636-643.
- Thompson, K., Kulkarni, J., dan Sergejew, A.A., 2000. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. *Schizophrenia research*, **42**: 241–247.
- Tseng, L.-N., Tseng, Y.-H., Jiang, Y.-D., Chang, C.-H., Chung, C.-H., Lin, B.J., dkk., 2012. Prevalence of hypertension and dyslipidemia and their associations with micro- and macrovascular diseases in patients with diabetes in Taiwan: An analysis of nationwide data for 2000–2009. *Journal of the Formosan Medical Association*, **111**: 625–636.
- Valdez, C.A. dan Ulrich, H., 2005. Similar Medication Compliance and Control of Dyslipidemia With Simvastatin or Atorvastatin in a Staff-Model HMO Medical Clinic. *Journal of Managed Care Pharmacy*, **11**: 499–504.
- Waspadji, S., Suryono, S., Sukarji, K., dan Kresnawan, S.A., 2010. *Pengkajian Status Gizi*. Balai penerbit FKUI, Jakarta.
- Wetherill, D. dan Kereiakes, D., 2002. *Kolesterol Tinggi*. PT. Elex Media Komputindo, Jakarta.

WHO, 1999. What is a healthy lifestyle.

Wilhelm, K., Handley, T., dan Reddy, P., 2016. Exploring the validity of the Fantastic Lifestyle Checklist in an inner city population of people presenting with suicidal behaviours. *Australian & New Zealand Journal of Psychiatry*, **50**: 128–134.

Xie, G., Zaman, M.J.S., Myint, P.K., Liang, L., Zhao, L., dan Wu, Y., 2013. Factors associated with compliance to lipid-lowering treatment in China. *European Journal of Preventive Cardiology*, **20**: 229–237.

Zodda, D., Giammona, R., dan Schifilliti, S., 2018. Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs. *Journal Pharmacy*, **6**: 2–16.